Outsourcing

Articles

WuXi XDC will provide end-to-end services to support Boostimmune’s discovery of novel bioconjugates.

WuXi XDC, Boostimmune Sign MOU

The collaboration partner for Willow is focused on more sustainable methods to manufacture intermediates and APIs at reduced cost and less waste, in addition to looking for Willow’s expertise in developing and scaling key ingredients. 

Willow Biosciences Announces Collaboration with Biopharma Company 

The deal is worth up to $36 million with an initial upfront consideration of $14 million, with an additional $22 million in contingent value rights (CVRs) that is payable upon achieving certain milestones.

LEO Pharma to Acquire Timber Pharmaceuticals

Shriya Bhatkhande is a research associate at BioPlan Associates.

More than a third of CMOs are struggling to keep skilled technical and production staff.  

Staffing Shortages:  Major Hurdle for Bioprocess Contract Manufacturing Services in 2023

Susan J. Schniepp is a fellow at Regulatory Compliance Associates, Inc. and a member of Pharmaceutical Technology's Editorial Advisory Board.

The more information shared, the smoother the approval process, says 
Susan J. Schniepp, distinguished fellow with Regulatory Compliance Associates. 

Sharing Critical Information for the Best Outcome

WuXi STA’s new high-potency injectable line has an annual capacity of 12 million units.

WuXi Sta Launches High Potency Manufacturing Line in Wuxi City Location

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Podcasts

In this episode, Sergey Vlasenko from Agilent chats about bio/pharmaceutical manufacturing trends, with a particular focus on oligonucleotides.

Drug Solutions Podcast: Unlocking the Latest Manufacturing Trends

To overcome the challenges of the widening range and scope of products that require aseptic processing and the evolving regulatory landscape in this field, companies should deepen their knowledge base on best practices.

Gaining a Deeper Understanding of Aseptic Needs

Detection of nitrosamines in several commercial drugs has resulted in manufacturing batch recalls followed by a review of the APIs’ synthesis processes by MAHs. 

Understanding Nitrosamine Impurities in the Pharmaceutical Industry

What factors do CDMOs consider vital to their success?

Contract Manufacturing, General